PMVP PMV Pharmaceuticals Inc.

FDA Catalyst Company
14.13
+1.49  (+12%)
Previous Close 12.65
Open 13.12
52 Week Low 11.44
52 Week High 37.3199
Market Cap $644,189,550
Shares 45,574,075
Float 36,584,540
Enterprise Value $310,594,641
Volume 464,492
Av. Daily Volume 917,100
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS EST. 1.82
EPS PRIOR. 1.82
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
Oppenheimer Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 03/02/2022
Goldman Sachs Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 09/22/2021
Oppenheimer Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 08/19/2021
Guggenheim Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 08/02/2021
HC Wainwright & Co. Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 07/29/2021

Latest News

    • Oral presentation at 2022 ASCO annual meeting to highlight initial data from ongoing Phase 1/2 PYNNACLE study of PC14586 in patients with advanced solid tumors

    CRANBURY, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the first quarter ended March 31, 2022, and provided a corporate update.

    "Our priority in 2022 is execution of the ongoing Phase 1/2 trial evaluating PC14586, our investigational first-in-class p53 Y220C reactivator, in patients with solid tumors, as well as continued progress on our pipeline" said David Mack…

    View Full Article
    • Oral presentation at ASCO to highlight initial data from ongoing Phase 1 study of PC14586, a first-in-class precision oncology investigational therapy, in patients with advanced solid tumors that have a p53 Y220C mutation

    CRANBURY, N.J., April 27, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that initial clinical data from the Phase 1 dose-escalation portion of the ongoing Phase 1/2 study evaluating PC14586 have been selected for oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, to take place June 3-7, in Chicago, Illinois.

    Details of

    View Full Article
    • Continued progress with Phase 1/2 study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors that have a p53 Y220C mutation
    • Strong cash, cash equivalents and marketable securities of $314.1 million as of December 31, 2021

    CRANBURY, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided corporate highlights.

    "We expect that 2022 will be another productive year for PMV Pharma, following accomplishments…

    View Full Article
  1. CRANBURY, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) --  PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President & Chief Executive Officer, will participate in a panel discussion on lung cancer at the 42nd Annual Cowen Health Care Conference taking place virtually March 7-9, 2022. The company will also be available to meet one-on-one with institutional investors at the conference.

    Details on the panel can be found below.

    Cowen's 42nd Annual Health Care Conference

    Date:Wednesday, March 9, 2022
    Time:
    Format:
    9:10 AM – 10:10 AM EST
    Corporate Panel Discussion
    Title:Lung Cancer
    View Full Article
  2. CRANBURY, N.J., Feb. 03, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced that David H. Mack, Ph.D., President & Chief Executive Officer, will represent PMV Pharmaceuticals in a "Fireside Chat" at the Guggenheim Healthcare Talks 2022 Oncology Day taking place on February 9, 2022. The company will also participate in one-on-one investor meetings at the conference.

    Details on the presentation can be found below.

    Guggenheim Healthcare Talks 2022 Oncology Day

    Date:Wednesday, February 9, 2022
    Time:
    10:30 am ET
    Format:Fireside Chat

    About PMV Pharma

    PMV Pharma is…

    View Full Article
View All PMV Pharmaceuticals Inc. News